Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227)

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 12, 2008, Pages 4432-4441

  Seiwert, Scott D ^a   Andrews, Steven W ^b   Jiang, Yutong ^b   Serebryany, Vladimir ^a   Tan, Hua ^a   Kossen, Karl ^a   Ravi Rajagopalan, P T ^a   Misialek, Shawn ^a   Stevens, Sarah K ^a   Stoycheva, Antitsa ^a   Hong, Jin ^a   Lim, Sharlene R ^a   Qin, Xiaoli ^a   Rieger, Robert ^b   Condroski, Kevin R ^b   Zhang, Hailong ^b   Do, Mary Geck ^b   Lemieux, Christine ^b   Hingorani, Gary P ^b   Hartley, Dylan P ^b   Josey, John A ^b   Pan, Lin ^a   Beigelman, Leonid ^a   Blatt, Lawrence M ^a   more..

^a InterMune Inc   (United States)

^b ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; CELL SURFACE RECEPTOR; CILUPREVIR; ION CHANNEL; ITMN 191; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RNA; TELAPREVIR; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; ASSAY; DRUG BINDING; DRUG INHIBITION; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITOR COMPLEX; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; ION TRANSPORT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REPLICON;

ANIMALS; ANTIVIRAL AGENTS; CARRIER PROTEINS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HEPACIVIRUS; HUMANS; INTERFERON ALFA-2A; LIVER; MACACA FASCICULARIS; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RATS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 57049176125     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00699-08     Document Type: Article

References (51)

1. Chang, T. T., and T. C. Chou. 2000. Rational approach to the clinical protocol design for drug combinations: a review. Acta Paediatr. Taiwan 41:294-302.
2. Chou, T. C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
3. Condroski, K. R., H. Zhang, S. D. Seiwert, J. A. Ballard, B. A. Bernat, B. Brandhuber, H. Colwell, D. Smith, G. Vigers, S. W. Andrews, A. L. Kennedy, Y. Jiang, S. M. Wenglowsky, J. A. Josey, and L. M. Blatt. 2006. Structure-based design of novel isoindolene inhibitors of HCV NS3/4A protease and binding mode analysis of ITMN 191 by X-ray crystallography. Gastroenterology 130:A-835.
4. Copeland, R. A. 2005. Evaluation of enzyme inhibitors in drug discovery, 1st ed. Wiley and Sons, Hoboken, NJ.
5. Dearlove, G. E., B. J. Marafino, Jr., J. T. Secrest, E. A. Smith, S. D. Seiwert, and L. M. Blatt. 2007. The safety evaluation of ITMN-191, a novel orally available hepatitis C serine protease inhibitor. Toxicologist 96:S1.
6. Evans, M., and A. Rees. 2002. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf. 25:649-663.
7. Evans, M., and A. Rees. 2002. The myotoxicity of statins. Curr. Opin. Lipidol. 13:415-420.
8. Forestier, N., H. W. Reesink, C. J. Weegink, L. McNair, T. L. Kieffer, H. M. Chu, S. Purdy, P. L. Jansen, and S. Zeuzem. 2007. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46:640-648.
9. Forestier, N., D. Larrey, D. Guyader, P. Marcellin, R. Rouzier, A. Patat, W. Bradford, S. Porter, and S. Zeuzem. 2008. Treatment of chronic hepatitis C virus (HCV) genotype 1 patients with the NS3/4A protease inhibitor ITMN-191 leads to rapid reductions in plasma HCV RNA: results of a phase 1b multiple ascending dose (MAD) study. Hepatology 48:1132A.
10. Fried, M. W., M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
11. Gale, M., Jr., and E. M. Foy. 2005. Evasion of intracellular host defense by hepatitis C virus. Nature 436:939-945.
12. He, Y., M. S. King, D. J. Kempf, L. Lu, H. B. Lim, P. Krishnan, W. Kati, T. Middleton, and A. Molla. 2008. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob. Agents Chemother. 52:1101-1110.
13. Hezode, C., P. Ferenci, G. Dusheiko, S. Pol, T. Goeser, J.-P. Bronowicki, S. Gharakhanian, D. Devonish, R. Kauffman, J. Alam, J.-M. Pawlotsky, and S. Zeuzem. 2007. PROVE2: phase II study of VX-950 (telaprevir) in combination with peginterferon alfa 2A with or without ribavirin in subjects with chronic hepatitis C, first interim analysis. Hepatology 46:268A-269A.
14. Hinrichsen, H., Y. Benhamou, H. Wedemeyer, M. Reiser, R. E. Sentjens, J. L. Calleja, X. Forns, A. Erhardt, J. Cronlein, R. L. Chaves, C. L. Yong, G. Nehmiz, and G. G. Steinmann. 2004. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127:1347-1355.
15. Jacobson, I. M., G. T. Everson, S. C. Gordon, R. Kauffman, L. McNair, A. Muir, and J. G. McHutchison. 2007. Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2A and ribavirin in treatment-naïve subjects with hepatitis C. Hepatology 46:315A-316A.
16. Kieffer, T., C. Sarrazin, J. Miller, S. Traver, Y. Zhou, D. Bartels, B. Hanzelka, U. Müh, C. Chao Lin, H. Reesink, A. A. Kwong, and S. Zeuzem. 2006. Combination of telaprevir (VX-950) and PEG-IFNalfa suppresses both wild-type virus and resistance variants in HCV genotype 1-infected patients in a 14-day phase 1b study. Hepatology 44:63A.
17. Kieffer, T. L., C. Sarrazin, J. S. Miller, M. W. Welker, N. Forestier, H. W. Reesink, A. D. Kwong, and S. Zeuzem. 2007. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46:631-639.
18. Koev, G., T. Dekhtyar, L. Han, P. Yan, T. I. Ng, C. T. Lin, H. Mo, and A. Molla. 2007. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Antivir. Res. 73:78-83.
19. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A. M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M. A. Poupart, J. Rancourt, R. E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C. L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
20. Lemon, S. M., M. Yi, and K. Li. 2005. "Strong reasons make strong actions" - the antiviral efficacy of NS3/4A protease inhibitors. Hepatology 41: 671-674.
21. Lin, C., C. A. Gates, B. G. Rao, D. L. Brennan, J. R. Fulghum, Y. P. Luong, J. D. Frantz, K. Lin, S. Ma, Y. Y. Wei, R. B. Perni, and A. D. Kwong. 2005. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. 280: 36784-36791.
22. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
23. National Institutes of Health. 2002. NIH consensus statement on management of hepatitis C: 2002. NIH Consens. State Sci. Statements 19:1-46.
24. Ni, Z. J., and A. S. Wagman. 2004. Progress and development of small molecule HCV antivirals. Curr. Opin. Drug Discov. Dev. 7:446-459.
25. Pawlotsky, J. M. 2004. Hepatitis C: it's a long way to new therapy, it's a long way to go. Gastroenterology 127:1629-1632.
26. Perni, R. B., S. J. Almquist, R. A. Byrn, G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, A. Heiser, G. Kalkeri, E. Kolaczkowski, K. Lin, Y. P. Luong, B. G. Rao, W. P. Taylor, J. A. Thomson, R. D. Tung, Y. Wei, A. D. Kwong, and C. Lin. 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50:899-909.
27. Perni, R. B., G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, C. A. Gates, S. L. Harbeson, A. D. Kwong, C. Lin, Y.-P. Luong, W. Markland, B. G. Rao, R. D. Tung, and J. A. Thomson. 2003. VX-950: the discovery of an inhibitor of the hepatitis C NS3 · 4A protease and a potential hepatitis C virus therapeutic. Hepatology 38:624A.
28. Pockros, P. J., D. Nelson, E. Godofsky, M. Rodriguez-Torres, G. Everson, M. W. Fried, R. H. Ghalib, S. A. Harrison, L. M. Nyberg, M. L. Shiffman, G. Z. Hill, and A. Chan. 2007. Robust synergistic antiviral effect of R1626 in combination with peginterferon alfa-2a (40KD), with or without ribavirin: interim analysis results of phase 2a study. Hepatology 46:311A.
29. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-205.
30. Rajagopalan, P. T. R., S. S. Misialek, L. M. Blatt, S. D. Seiwert, and K. Kossen. 2007. Characterization of HCV NA3/4a protease inhibition by ITMN 191 reveals picomolar potency and slow dissociation: implications for the use of ITMN 191 in chronic HCV treatment. Gastroenterology 132:A-782.
31. Reesink, H. W., S. Zeuzem, C. J. Weegink, N. Forestier, A. van Vliet, J. van de Wetering de Rooij, L. McNair, S. Purdy, R. Kauffman, J. Alam, and P. L. Jansen. 2006. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131:997-1002.
32. Reiser, M., H. Hinrichsen, Y. Benhamou, H. W. Reesink, H. Wedemeyer, C. Avendano, N. Riba, C. L. Yong, G. Nehmiz, and G. G. Steinmann. 2005. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41:832-835.
33. Rieger, R. A., P. A. Lee, S. D. Seiwert, S. W. Andrews, T. K. Pope, J. Pheneger, N. N. Neitzel, R. B. Franklin, J. A. Josey, and L. M. Blatt. 2006. Pharmacokinetic analysis and liver concentrations of a series of macrocyclic peptidomimetic inhibitors of HCV NS3/4A protease: identification of ITMN-191, a potent NS3/4A protease inhibitor with high liver exposure across multiple species. Gastroenterology 130:A-835.
34. Rubino, C., W. Bradford, A. Forrest, S. Porter, L. Blatt, S. Seiwert, and S. Zeuzem. 2008. Pharmacokinetic-pharmacodynamic (PK-PD) relationships for ITMN-191 in a phase 1 multiple ascending dose trial in patients with genotype 1 chronic hepatitis C (CHC) infection. Hepatology 48:1140A.
35. Sarrazin, C., T. L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, M. Welker, D. Wincheringer, Y. Zhou, H. M. Chu, C. Lin, C. Weegink, H. Reesink, S. Zeuzem, and A. D. Kwong. 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767-1777.
36. Sarrazin, C., R. Rouzier, F. Wagner, N. Forestier, D. Larrey, S. K. Gupta, M. Hussain, A. Shah, D. Cutler, J. Zhang, and S. Zeuzem. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132:1270-1278.
37. Sculley, M. J., J. F. Morrison, and W. W. Cleland. 1996. Slow-binding inhibition: the general case. Biochim. Biophys. Acta 1298:78-86.
38. Seiwert, S. D., S. W. Andrews, H. Tan, K. R. Condroski, J. A. Ballard, B. A. Bernat, J. A. Josey, and L. M. Blatt. 2006. Generation and characterization of HCV replicons with reduced sensitivity to ITMN 191, a macrocyclic inhibitor of NS3/4A. Gastroenterology 130:A-754.
39. Shepard, C. W., L. Finelli, and M. J. Alter. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5:558-567.
40. Simmen, K., O. Lenz, T. Lin, G. Fanning, P. Raboisson, H. de Kock, G. van't Klooster, Å. Rosenquist, M. Edlund, M. Nilsson, L. Vrang, and B. Samuelsson. 2007. In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor, TMC435350. Hepatology 46:857A.
41. Sumpter, R., Jr., C. Wang, E. Foy, Y. M. Loo, and M. Gale, Jr. 2004. Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J. Virol. 78:11591-11604.
42. Szedlacsek, S. E., and R. G. Duggleby. 1995. Kinetics of slow and tight-binding inhibitors. Methods Enzymol. 249:144-180.
43. Tan, H., J. Derrick, J. Hong, C. Sanda, W. M. Grosse, H. J. Edenberg, M. Taylor, S. Seiwert, and L. M. Blatt. 2005. Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses. J. Interferon Cytokine Res. 25:632-649.
44. Thimme, R., V. Lohmann, and F. Weber. 2006. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antivir. Res. 69:129-141.
45. Thomson, J. A., and R. B. Perni. 2006. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. Curr. Opin. Drug Discov. Dev. 9:606-617.
46. Tong, X., R. Chase, A. Skelton, T. Chen, J. Wright-Minogue, and B. A. Malcolm. 2006. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antivir. Res. 70:28-38.
47. van 't Klooster, G. A. E., I. Vanwelkenhuysen, R. Hooijmaijers, K. Bol, M. Voets, J. Van Houdt, R. A. L. Verloes, F. Aharchi, K. Marien, P. Van Remoortere, F. Broeckaert, H. de Kock, and K. A. Simmen. 2008. Once daily regimens of the HCV NS3/4A-protease inhibitor TMC435350 are predicted to provide therapeutic exposure in plasma and liver. J. Hepatol 48:S321.
48. Venkatraman, S., S. L. Bogen, A. Arasappan, F. Bennett, K. Chen, E. Jao, Y. T. Liu, R. Lovey, S. Hendrata, Y. Huang, W. Pan, T. Parekh, P. Pinto, V. Popov, R. Pike, S. Ruan, B. Santhanam, B. Vibulbhan, W. Wu, W. Yang, J. Kong, X. Liang, J. Wong, R. Liu, N. Butkiewicz, R. Chase, A. Hart, S. Agrawal, P. Ingravallo, J. Pichardo, R. Kong, B. Baroudy, B. Malcolm, Z. Guo, A. Prongay, V. Madison, L. Broske, X. Cui, K. C. Cheng, Y. Hsieh, J. M. Brisson, D. Prelusky, W. Korfmacher, R. White, S. Bogdanowich-Knipp, A. Pavlovsky, P. Bradley, A. K. Saksena, A. Ganguly, J. Piwinski, V. Girijavallabhan, and F. G. Njoroge. 2006. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3- dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3, 3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J. Med. Chem. 49:6074-6086.
49. Verloes, R., K. A. Farha, A. van Vliet, G. van't Klooster, F. Aharchi, K. Marien, H. de Kock, and K. Kenneth Simmen. 2007. Results of a phase 1 placebo-controlled trial in healthy volunteers to examine the safety, tolerability and pharmacokinetics of the HCV protease inhibitor TMC435350 after single and repeated dosing. Hepatology 46:823A.
50. Williams, J. W., and J. F. Morrison. 1979. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63:437-467.
51. Wolfenden, R. 1976. Transition state analog inhibitors and enzyme catalysis. Annu. Rev. Biophys. Bioeng. 5:271-306.